{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.20","value":"23.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"All subjects received bortezomib 1.3mg/m\\^2 on Days 1, 4, 15, and 18 every 28 days and dexamethasone 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days. Following US FDA approval of doxorubicin HCl liposome injection in combination with bortezomib in May 2007, the study was amended to allow combination treatment with both bortezomib and doxorubicin HCl liposome injection 30 mg/m\\^2 on Day 4 every 28 days with dexamethasone. The target goal was 8 cycles of treatment.","id":"OG000","title":"Treatment Group"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"TTP was measured from day 1 of treatment until time of progression, assessed up to 40 months","title":"Time to Progression (TTP)","type":"SECONDARY","unitOfMeasure":"Months"}